Navigation Links
RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
Date:8/25/2008

Company Receives Approval from Chinese Health Authorities to Launch Final

Clinical Trial for Asacard(R)

NEW HAVEN, Conn., Aug. 25 /PRNewswire/ -- RHEI Pharmaceuticals, Inc. today announced the appointment of Dr. Geert Cauwenbergh as Chief Executive Officer. Dr. Cauwenbergh succeeds Joos Horsten, who recently passed away. Dr Cauwenbergh has been assisting RHEI Pharmaceuticals since August 1, 2008 in providing the necessary leadership to continue the Company's development.

"I am honored to follow in the footsteps of Joos Horsten, a serial entrepreneur who was a key figure in the development of the Western pharmaceutical industry in China," noted Dr. Cauwenbergh. "As a result of Joos' leadership and foresight, RHEI Pharmaceuticals is uniquely positioned to accelerate the availability of already approved western medicines in the Chinese market and I am fortunate to be working with the world-class team that Joos had assembled in order to pursue its growth strategy."

The Company also announced today that it has received approval from the Chinese Health Authorities to launch its final clinical study for Asacard(R), a controlled release formulation of aspirin. With this approval in place, RHEI Pharmaceuticals has a low-risk pipeline of novel western medicines lined up for the Chinese market, with multiple product launches expected over the next few years.

Commenting on this news, Dr. Cauwenbergh stated, "With one potential launch this year, followed by three in 2009 (including Asacard(R)) and an additional product launch planned each year thereafter until 2012, RHEI Pharmaceuticals is expected to achieve very rapid growth. It is our goal to become the partner of choice for western companies that want to tap into the fast growing Chinese Health Care market, as well as for those Chinese companies that are interested in distributing western drugs, domestically."

Prior to joining RHEI Pharmaceuticals, in February 2
'/>"/>

SOURCE RHEI Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
4. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
5. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
6. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on the ... of the global Propanol market with a focus on the Chinese situation. Major companies ... Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Aug. 26 Bio-Reaction Industries is,pleased to announce ... executive,David Skiven as the newest member on their ... environmentally responsible innovations that Mr.,Skiven oversaw during his ... Group at GM, it,s logical that he would ...
... for Biopharmaceutical, Cell,Culture, Life Science Research and Diagnostics Industry Adds ... Productivity, ... Safety and Time to Market, FORT ... global supplier of animal free,products that enhance productivity, safety and ...
... NEEDHAM, Massachusetts, August 26 /PRNewswire-FirstCall/,-- Oridion Systems ... agreement with,Spacelabs Healthcare, a leading global medical ... now employs Oridion Microstream(R),capnography technology in its ... Spacelabs Healthcare, recognizing the importance of ...
Cached Biology Technology:GM Exec Joins Bio-Reaction Industries' Board of Directors 2InVitria Expands Sales Team 2InVitria Expands Sales Team 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 2Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 4
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Knut Stamnes, Professor and Department Director of Physics ... has been awarded a NASA grant for work ... satellite. His proposal to "use and further develop ... coupled atmosphere-surface systems" is funded as part of ...
... Senior Design team at Stevens Institute of Technology is ... arise during thoracic surgeries. Five undergraduate Biomedical Engineering students ... of existing catheter design and introduces a potentially profitable ... the efforts of the Stevens Innovative Fluid Extraction System ...
... revealing how age-old irrigation techniques may have boosted the ... an estimated 200 million people today. ... kingdom that was located in present-day Sudan, provides details ... disease across populations in ancient times, and how human ...
Cached Biology News:Dr. Knut Stamnes at Stevens receives NASA grant for environmental monitoring 2Dr. Knut Stamnes at Stevens receives NASA grant for environmental monitoring 3Stevens thoracic catheter senior design team takes 1st place at regional ISPE competition 2Stevens thoracic catheter senior design team takes 1st place at regional ISPE competition 3Mummies tell history of a 'modern' plague 2Mummies tell history of a 'modern' plague 3